Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIO-TECHNE CorpTECH · Entity 3479 | President-Protein Sciences | November 12, 2021 | November 16, 2021 |
| Marker Therapeutics, Inc.MRKR · Entity 7609 | Director | November 17, 2025 | November 19, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIO-TECHNE Corp
Report date November 12, 2021 · Filed November 16, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,117 |
Ending reported balance
After 2021-11-16 transaction · row 12
12 source rows · reconciled sequenceRow 1 · 2021-11-12 · Exercise / conversion · Acquired 27,159 · Balance 28,477 Row 2 · 2021-11-12 · Sale · Disposed 700 · Balance 27,777 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $503.78 to $504.535, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2021-11-12 · Sale · Disposed 200 · Balance 27,577 Row 4 · 2021-11-12 · Sale · Disposed 300 · Balance 27,277 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $502.62 to $503.33, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 5 · 2021-11-12 · Sale · Disposed 537 · Balance 26,740 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $503.77 to $504.745, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 6 · 2021-11-12 · Sale · Disposed 400 · Balance 26,340 F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $504.97 to $505.11, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 7 · 2021-11-12 · Sale · Disposed 4,054 · Balance 22,286 F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $502.11 to $503.10, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 8 · 2021-11-12 · Sale · Disposed 9,043 · Balance 13,243 F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $503.11 to $504.107, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 9 · 2021-11-12 · Sale · Disposed 8,989 · Balance 4,254 F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $504.13 to $505.11, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 10 · 2021-11-12 · Sale · Disposed 2,535 · Balance 1,719 F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $505.13 to $506.07, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 11 · 2021-11-12 · Sale · Disposed 401 · Balance 1,318 F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $506.20 to $506.275, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 12 · 2021-11-16 · Exercise / conversion · Acquired 799 · Balance 2,117 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $125.05 · Expires 2024-08-09 | Direct | 799 |
Reported balance
After 2021-11-12 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2021-11-12 · Exercise / conversion · Disposed 27,159 · Balance 799 F11: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $125.05 · Expires 2024-08-09 | Direct | 0 |
Reported balance
After 2021-11-16 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2021-11-16 · Exercise / conversion · Disposed 799 · Balance 0 F11: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $177.32 · Expires 2025-08-08 | Direct | 13,550 |
Reported balance
Holding disclosure · report date 2021-11-12 · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · Balance 13,550 F11: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $177.32 · Expires 2025-08-08 | Direct | 18,066 |
Reported balance
Holding disclosure · report date 2021-11-12 · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · Balance 18,066 F12: Options to purchase 4,517 shares vest on each of 8/8/2019 and 8/8/2020 and options to purchase 4,516 shares vest on each of 8/8/2021 and 8/8/2022. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $190.41 · Expires 2026-08-07 | Direct | 15,948 |
Reported balance
Holding disclosure · report date 2021-11-12 · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · Balance 15,948 F13: Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $190.41 · Expires 2026-08-07 | Direct | 21,265 |
Reported balance
Holding disclosure · report date 2021-11-12 · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · Balance 21,265 F14: Options to purchase 5,317 shares vest on 8/7/2020 and options to purchase 5,316 shares vest on each of 8/7/2021, 8/7/2022 and 8/7/2023. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $267.87 · Expires 2027-08-05 | Direct | 11,488 |
Reported balance
Holding disclosure · report date 2021-11-12 · row 21
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 21 · Balance 11,488 F15: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $267.87 · Expires 2027-08-05 | Direct | 15,318 |
Reported balance
Holding disclosure · report date 2021-11-12 · row 22
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 22 · Balance 15,318 F16: Options to purchase 3,830 shares vest on each of 8/5/2021 and 8/5/2022 and options to purchase 3,829 shares vest on each of 8/5/2023 and 8/5/2024. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $267.87 · Expires 2027-08-05 | Direct | 24,975 |
Reported balance
Holding disclosure · report date 2021-11-12 · row 23
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 23 · Balance 24,975 F17: Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $267.87 · Expires 2027-08-05 | Direct | 24,975 |
Reported balance
Holding disclosure · report date 2021-11-12 · row 24
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 24 · Balance 24,975 F18: Options to purchase 8,325 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $481.82 · Expires 2028-08-06 | Direct | 6,080 |
Reported balance
Holding disclosure · report date 2021-11-12 · row 26
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 26 · Balance 6,080 F19: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $481.82 · Expires 2028-08-06 | Direct | 8,107 |
Reported balance
Holding disclosure · report date 2021-11-12 · row 27
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 27 · Balance 8,107 F20: Options to purchase 2,027 shares vest on each of 8/6/2022, 8/6/2023 and 8/6/2024 and options to purchase 2,026 shares vest on 8/6/2025. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 3,151 |
Reported balance
Holding disclosure · report date 2021-11-12 · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · Balance 3,151 F10: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F13: Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 2,575 |
Reported balance
Holding disclosure · report date 2021-11-12 · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · Balance 2,575 F10: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F15: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,556 |
Reported balance
Holding disclosure · report date 2021-11-12 · row 25
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 25 · Balance 1,556 F10: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F19: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $503.78 to $504.535, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $502.62 to $503.33, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $503.77 to $504.745, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $504.97 to $505.11, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $502.11 to $503.10, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $503.11 to $504.107, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $504.13 to $505.11, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $505.13 to $506.07, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $506.20 to $506.275, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F10: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
F11: Fully exercisable.
F12: Options to purchase 4,517 shares vest on each of 8/8/2019 and 8/8/2020 and options to purchase 4,516 shares vest on each of 8/8/2021 and 8/8/2022.
F13: Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F14: Options to purchase 5,317 shares vest on 8/7/2020 and options to purchase 5,316 shares vest on each of 8/7/2021, 8/7/2022 and 8/7/2023.
F15: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F16: Options to purchase 3,830 shares vest on each of 8/5/2021 and 8/5/2022 and options to purchase 3,829 shares vest on each of 8/5/2023 and 8/5/2024.
F17: Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021.
F18: Options to purchase 8,325 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023.
F19: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F20: Options to purchase 2,027 shares vest on each of 8/6/2022, 8/6/2023 and 8/6/2024 and options to purchase 2,026 shares vest on 8/6/2025.
Marker Therapeutics, Inc.
Report date November 17, 2025 · Filed November 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.95 · Expires 2035-11-17 | Direct | 84,411 |
Reported balance
After 2025-11-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-11-17 · Grant · Acquired 84,411 · Balance 84,411 F1: Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for the remaining options due as service as a director for the year 2024. 30,000 shares were previously granted on February 12, 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.95 · Expires 2035-11-17 | Direct | 137,330 |
Reported balance
After 2025-11-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-11-17 · Grant · Acquired 137,330 · Balance 137,330 F2: Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for service as a director for the year 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for the remaining options due as service as a director for the year 2024. 30,000 shares were previously granted on February 12, 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025.
F2: Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for service as a director for the year 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 29, 2020 Filed Jun 1, 2020 21:58 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 7,909 | $0.00 Strike: $108.49 | $0.00 |
DisclosureSEC source: 0000914190-20-000195 · edgar.xml · derivative · entry 9 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,909 shares Expires 2022-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully exercisable. Read SEC document |
| May 29, 2020 Filed Jun 1, 2020 21:58 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 709 | $264.01 | $187,184.44 |
DisclosureSEC source: 0000914190-20-000195 · edgar.xml · nonDerivative · entry 7 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $263.6168 to $264.5700, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 29, 2020 Filed Jun 1, 2020 21:58 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 2,100 | $262.68 | $551,619.39 |
DisclosureSEC source: 0000914190-20-000195 · edgar.xml · nonDerivative · entry 6 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 709 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $262.3150 to $263.2300, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 29, 2020 Filed Jun 1, 2020 21:58 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 3,400 | $261.74 | $889,926.54 |
DisclosureSEC source: 0000914190-20-000195 · edgar.xml · nonDerivative · entry 5 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,809 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $261.2500 to $262.2400, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 29, 2020 Filed Jun 1, 2020 21:58 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 1,700 | $260.83 | $443,409.64 |
DisclosureSEC source: 0000914190-20-000195 · edgar.xml · nonDerivative · entry 4 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,209 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $260.2500 to $261.2100, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 29, 2020 Filed Jun 1, 2020 21:58 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 7,909 | $108.49 | $858,047.41 |
DisclosureSEC source: 0000914190-20-000195 · edgar.xml · nonDerivative · entry 3 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,909 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 21:58 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 3,448 | $0.00 Strike: $108.49 | $0.00 |
DisclosureSEC source: 0000914190-20-000195 · edgar.xml · derivative · entry 8 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,909 Underlying: Common Stock · 3,448 shares Expires 2022-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully exercisable. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 21:58 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 3,448 | $260.19 | $897,134.09 |
DisclosureSEC source: 0000914190-20-000195 · edgar.xml · nonDerivative · entry 2 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $260.0000 to $260.6600, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 21:58 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 3,448 | $108.49 | $374,073.52 |
DisclosureSEC source: 0000914190-20-000195 · edgar.xml · nonDerivative · entry 1 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,448 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 22, 2020 Filed May 26, 2020 21:13 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 8,637 | $0.00 Strike: $108.49 | $0.00 |
DisclosureSEC source: 0000914190-20-000183 · edgar.xml · derivative · entry 10 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,357 Underlying: Common Stock · 8,637 shares Expires 2022-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully exercisable. Read SEC document |
| May 22, 2020 Filed May 26, 2020 21:13 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 3,963 | $0.00 Strike: $94.35 | $0.00 |
DisclosureSEC source: 0000914190-20-000183 · edgar.xml · derivative · entry 9 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,963 shares Expires 2021-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully exercisable. Read SEC document |
| May 22, 2020 Filed May 26, 2020 21:13 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 4,924 | $268.41 | $1,321,636.07 |
DisclosureSEC source: 0000914190-20-000183 · edgar.xml · nonDerivative · entry 7 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $268.09 to $268.81, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 22, 2020 Filed May 26, 2020 21:13 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 7,676 | $267.63 | $2,054,289.50 |
DisclosureSEC source: 0000914190-20-000183 · edgar.xml · nonDerivative · entry 6 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,924 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $267.09 to $268.05, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 22, 2020 Filed May 26, 2020 21:13 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 8,637 | $108.49 | $937,028.13 |
DisclosureSEC source: 0000914190-20-000183 · edgar.xml · nonDerivative · entry 5 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 22, 2020 Filed May 26, 2020 21:13 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 3,963 | $94.35 | $373,909.05 |
DisclosureSEC source: 0000914190-20-000183 · edgar.xml · nonDerivative · entry 4 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,963 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2020 Filed May 26, 2020 21:13 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 11,037 | $0.00 Strike: $94.35 | $0.00 |
DisclosureSEC source: 0000914190-20-000183 · edgar.xml · derivative · entry 8 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,963 Underlying: Common Stock · 11,037 shares Expires 2021-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully exercisable. Read SEC document |
| May 21, 2020 Filed May 26, 2020 21:13 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 900 | $268.89 | $241,996.50 |
DisclosureSEC source: 0000914190-20-000183 · edgar.xml · nonDerivative · entry 3 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $268.58 to $269.32, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 21, 2020 Filed May 26, 2020 21:13 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 10,137 | $267.37 | $2,710,319.55 |
DisclosureSEC source: 0000914190-20-000183 · edgar.xml · nonDerivative · entry 2 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $267.02 to $267.75, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 21, 2020 Filed May 26, 2020 21:13 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 11,037 | $94.35 | $1,041,340.95 |
DisclosureSEC source: 0000914190-20-000183 · edgar.xml · nonDerivative · entry 1 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 19, 2020 Filed Feb 12, 2021 22:11 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GrantCommon Stock | 17,022 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-010224 · doc5.xml · nonDerivative · entry 1 Eansor Norman David · CIK 0001270905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,282 F1 · shares: Represents the portion of the annual board retainer for each non-employee director payable in immediately vested common stock under the Company's 2014 Omnibus Stock Ownership Plan, as amended and based on the closing price of $2.35 per share, on the day immediately preceding the date of the Company's 2019 annual meeting. Read SEC document |
| March 04, 2020 Filed Mar 6, 2020 21:08 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 1,387 | $198.68 | $275,569.16 |
DisclosureSEC source: 0000914190-20-000109 · edgar.xml · nonDerivative · entry 1 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.60 to $198.75, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 19, 2019 Filed Aug 21, 2019 20:34 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 2,287 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-19-000331 · edgar.xml · derivative · entry 6 Eansor Norman David · CIK 0001270905 · SVP - Novus Biologicals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,287 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F3 · derivative.exercise_date: On 8/19/2019, the Board of Directors certified vesting of 2,287 performance RSUs. F3 · derivative.expiration_date: On 8/19/2019, the Board of Directors certified vesting of 2,287 performance RSUs. Read SEC document |
| August 19, 2019 Filed Aug 21, 2019 20:34 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 900 | $197.57 | $177,813.00 |
DisclosureSEC source: 0000914190-19-000331 · edgar.xml · nonDerivative · entry 2 Eansor Norman David · CIK 0001270905 · SVP - Novus Biologicals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,387 Read SEC document |
| August 19, 2019 Filed Aug 21, 2019 20:34 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 2,287 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000914190-19-000331 · edgar.xml · nonDerivative · entry 1 Eansor Norman David · CIK 0001270905 · SVP - Novus Biologicals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,287 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. Read SEC document |
| August 07, 2019 Filed Aug 9, 2019 20:11 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 21,265 | $0.00 Strike: $190.41 | $0.00 |
DisclosureSEC source: 0000914190-19-000260 · edgar.xml · derivative · entry 16 Eansor Norman David · CIK 0001270905 · SVP - Novus Biologicals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,265 Underlying: Common Stock · 21,265 shares Expires 2026-08-07 F10 · derivative.exercise_date: Options to purchase 5,317 shares vest on 8/7/2020 and options to purchase 5,316 shares vest on each of 8/7/2021, 8/7/2022 and 8/7/2023. Read SEC document |
| August 07, 2019 Filed Aug 9, 2019 20:11 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 15,948 | $0.00 Strike: $190.41 | $0.00 |
DisclosureSEC source: 0000914190-19-000260 · edgar.xml · derivative · entry 15 Eansor Norman David · CIK 0001270905 · SVP - Novus Biologicals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,948 Underlying: Common Stock · 15,948 shares Expires 2026-08-07 F9 · derivative.exercise_date: Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 07, 2019 Filed Aug 9, 2019 20:11 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 3,151 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-19-000260 · edgar.xml · derivative · entry 14 Eansor Norman David · CIK 0001270905 · SVP - Novus Biologicals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,151 Underlying: Common Stock · 3,151 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F9 · derivative.exercise_date: Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F9 · derivative.expiration_date: Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 20:13 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 3,117 | $215.00 | $670,155.00 |
DisclosureSEC source: 0001562180-19-003526 · primarydocument.xml · nonDerivative · entry 1 Eansor Norman David · CIK 0001270905 · SVP - Novus Biologicals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2019. Read SEC document |
| May 09, 2019 Filed May 13, 2019 20:02 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GrantCommon Stock | 7,260 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-025608 · tv521409_4.xml · nonDerivative · entry 1 Eansor Norman David · CIK 0001270905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,260 F1 · shares: Represents the portion of the annual board retainer for each non-employee director payable in immediately vested, common stock under the Company's 2014 Omnibus Stock Ownership Plan, as amended and based on the closing price of $5.51 per share, on the day immediately preceding the date of the Company's 2019 annual meeting. Read SEC document |
| October 17, 2018 Filed Oct 19, 2018 20:53 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GrantNon-Employee Director Stock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $8.34 | $0.00 |
DisclosureSEC source: 0001144204-18-054586 · tv505080_4.xml · derivative · entry 1 Eansor Norman David · CIK 0001270905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires not disclosed F1 · security: Represents options granted under the Company's 2014 Omnibus Stock Ownership Plan, as amended, in connection with the non-employee director compensation program upon appointment as a director of the Company on October 17, 2018. These shares vest in monthly installments over a two year period. The option exercise price is the closing price on the date of the grant, October 17, 2018. F1 · derivative.exercise_date: Represents options granted under the Company's 2014 Omnibus Stock Ownership Plan, as amended, in connection with the non-employee director compensation program upon appointment as a director of the Company on October 17, 2018. These shares vest in monthly installments over a two year period. The option exercise price is the closing price on the date of the grant, October 17, 2018. F1 · derivative.expiration_date: Represents options granted under the Company's 2014 Omnibus Stock Ownership Plan, as amended, in connection with the non-employee director compensation program upon appointment as a director of the Company on October 17, 2018. These shares vest in monthly installments over a two year period. The option exercise price is the closing price on the date of the grant, October 17, 2018. Read SEC document |
| August 08, 2018 Filed Aug 9, 2018 22:29 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to buy) · Derivative | 13,550 | $0.00 Strike: $177.32 | $0.00 |
DisclosureSEC source: 0001562180-18-003544 · primarydocument.xml · derivative · entry 8 Eansor Norman David · CIK 0001270905 · SVP - Novus Biologicals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,550 Underlying: Common Stock · 13,550 shares Expires 2025-08-08 F4 · derivative.exercise_date: Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 08, 2018 Filed Aug 9, 2018 22:29 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to buy) · Derivative | 18,066 | $0.00 Strike: $177.32 | $0.00 |
DisclosureSEC source: 0001562180-18-003544 · primarydocument.xml · derivative · entry 7 Eansor Norman David · CIK 0001270905 · SVP - Novus Biologicals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,066 Underlying: Common Stock · 18,066 shares Expires 2025-08-08 F5 · derivative.exercise_date: Vests 4,517 shares each on 8/8/2019, 8/8/2020 and 4,516 shares each on 8/8/2021, 8/8/2022. Read SEC document |
| August 08, 2018 Filed Aug 9, 2018 22:29 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 2,537 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003544 · primarydocument.xml · derivative · entry 6 Eansor Norman David · CIK 0001270905 · SVP - Novus Biologicals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,537 Underlying: Common Stock · 2,537 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F4 · derivative.exercise_date: Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F4 · derivative.expiration_date: Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 22:29 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Disposition to issuerStock Options (Right to buy) · Derivative | 1,881 | $0.00 Strike: $108.49 | $0.00 |
DisclosureSEC source: 0001562180-18-003544 · primarydocument.xml · derivative · entry 5 Eansor Norman David · CIK 0001270905 · SVP - Novus Biologicals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,494 Underlying: Common Stock · 1,881 shares Expires 2022-08-07 F3 · derivative.exercise_date: On 8/7/2018, the Board of Directors authorized discretionary vesting for 7,494 performance options. The remainder of the performance options were forfeited. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 22:29 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Disposition to issuerRestricted Stock Units · Derivative | 301 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003544 · primarydocument.xml · derivative · entry 4 Eansor Norman David · CIK 0001270905 · SVP - Novus Biologicals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 301 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: On 8/7/2018, the Board of Directors authorized discretionary vesting for 1,199 performance RSUs. The remainder of the performance RSUs were forfeited. F2 · derivative.expiration_date: On 8/7/2018, the Board of Directors authorized discretionary vesting for 1,199 performance RSUs. The remainder of the performance RSUs were forfeited. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 22:29 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 1,199 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003544 · primarydocument.xml · derivative · entry 3 Eansor Norman David · CIK 0001270905 · SVP - Novus Biologicals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301 Underlying: Common Stock · 1,199 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: On 8/7/2018, the Board of Directors authorized discretionary vesting for 1,199 performance RSUs. The remainder of the performance RSUs were forfeited. F2 · derivative.expiration_date: On 8/7/2018, the Board of Directors authorized discretionary vesting for 1,199 performance RSUs. The remainder of the performance RSUs were forfeited. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 22:29 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 348 | $180.14 | $62,688.72 |
DisclosureSEC source: 0001562180-18-003544 · primarydocument.xml · nonDerivative · entry 2 Eansor Norman David · CIK 0001270905 · SVP - Novus Biologicals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,117 Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 22:29 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 1,199 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003544 · primarydocument.xml · nonDerivative · entry 1 Eansor Norman David · CIK 0001270905 · SVP - Novus Biologicals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,465 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2018 Filed May 11, 2018 20:16 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 1,136 | $145.19 | $164,931.75 |
DisclosureSEC source: 0001562180-18-002455 · primarydocument.xml · nonDerivative · entry 1 Eansor Norman David · CIK 0001270905 · SVP - Novus Biologicals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,266 Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 20:56 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to buy) · Derivative | 15,976 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0001562180-17-003379 · primarydocument.xml · derivative · entry 4 Eansor Norman David · CIK 0001270905 · SVP - Novus Biologicals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,976 Underlying: Common Stock · 15,976 shares Expires 2024-08-09 F3 · derivative.exercise_date: Vest 3,994 shares on each 8/9/2018, 8/9/2019, 8/9/2020, 8/9/2021 Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 20:56 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to buy) · Derivative | 11,982 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0001562180-17-003379 · primarydocument.xml · derivative · entry 3 Eansor Norman David · CIK 0001270905 · SVP - Novus Biologicals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,982 Underlying: Common Stock · 11,982 shares Expires 2024-08-09 F2 · derivative.exercise_date: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 20:56 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 2,174 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-003379 · primarydocument.xml · derivative · entry 2 Eansor Norman David · CIK 0001270905 · SVP - Novus Biologicals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,174 Underlying: Common Stock · 2,174 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F2 · derivative.expiration_date: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| July 01, 2017 Filed Jul 5, 2017 21:46 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 534 | $117.50 | $62,745.00 |
DisclosureSEC source: 0001562180-17-002413 · primarydocument.xml · nonDerivative · entry 1 Eansor Norman David · CIK 0001270905 · SVP - Novus Biologicals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,402 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.